Ainos Announces GICS Reclassification to Information Technology Sector
Ainos (NASDAQ:AIMD) announced its reclassification under GICS to Technology Hardware, Storage & Peripherals sector (Code 45202030), effective October 1, 2025. The company, transitioning from biotechnology, is positioning itself as a technology innovator in digital olfaction with its AI Nose platform powered by smell language model (SLM).
Key achievements include a 435% year-over-year revenue growth in 1H 2025 from senior care initiatives in Japan and securing a $2.1 million multi-year SmellTech-as-a-Service subscription contract for semiconductor manufacturing. Ainos has established strategic partnerships with five industry leaders: ASE Technology Holding, Topco Scientific, Kenmec Mechanical Engineering, Solomon Technology, and ugo, Inc., to accelerate SmellTech adoption across semiconductors, robotics, and automation sectors.
Ainos (NASDAQ:AIMD) ha annunciato la sua riclassificazione secondo GICS nel settore Technology Hardware, Storage & Peripherals (Codice 45202030), con effetto dal 1 ottobre 2025. L'azienda, in fase di transizione dalla biotecnologia, si posiziona come innovatrice tecnologica nel campo dell'olfazione digitale con la sua piattaforma AI Nose alimentata dal modello linguistico dell'odore (SLM).
Principali traguardi includono una crescita del 435% del fatturato su base annua nel primo semestre 2025 derivante da iniziative nel settore dell'assistenza agli anziani in Giappone e la definizione di un contratto di sottoscrizione pluriennale di SmellTech-as-a-Service del valore di $2,1 milioni per la produzione di semiconduttori. Ainos ha stretto partnership strategiche con cinque leader del settore: ASE Technology Holding, Topco Scientific, Kenmec Mechanical Engineering, Solomon Technology e ugo, Inc., per accelerare l'adozione di SmellTech nei settori dei semiconduttori, della robotica e dell'automazione.
Ainos (NASDAQ:AIMD) anunció su reclasificación conforme a GICS al sector Technology Hardware, Storage & Peripherals (Código 45202030), con efecto a partir del 1 de octubre de 2025. La empresa, en transición desde la biotecnología, se posiciona como innovadora tecnológica en olfacción digital con su plataforma AI Nose impulsada por el modelo de lenguaje del olor (SLM).
Entre los logros clave se destacan un crecimiento del 435% interanual de ingresos en el primer semestre de 2025 gracias a iniciativas de cuidado de personas mayores en Japón y la obtención de un contrato de suscripción plurianual de SmellTech-as-a-Service por $2,1 millones para la fabricación de semiconductores. Ainos ha establecido asociaciones estratégicas con cinco líderes de la industria: ASE Technology Holding, Topco Scientific, Kenmec Mechanical Engineering, Solomon Technology y ugo, Inc., para acelerar la adopción de SmellTech en semiconductores, robótica y sectores de automatización.
Ainos (NASDAQ:AIMD)가 2025년 10월 1일부로 기술주 헤드라인의 기술 하드웨어, 저장 및 주변 기기 섹터(코드 45202030)로 GICS 분류 재지정되었습니다. 생명공학에서 전환 중인 이 회사는 디지털 후각 기술의 기술 혁신자로 자리매김하고 있으며, 그 플랫폼은 냄새 언어 모델(SLM)이 적용된 AI 노즈 플랫폼입니다.
주요 성과로는 2025년 상반기 일본의 노인 케어 이니셔티브로 인한 전년 동기 대비 매출 435% 성장과 반도체 제조를 위한 210만 달러 규모의 다년 구독 계약(SmellTech-as-a-Service)을 확보한 점이 있습니다. Ainos는 반도체, 로봇 공학 및 자동화 분야에서 SmellTech 채택을 가속하기 위해 ASE Technology Holding, Topco Scientific, Kenmec Mechanical Engineering, Solomon Technology, 및 ugo, Inc. 등 다섯 업계 리더와 전략적 파트너십을 체결했습니다.
Ainos (NASDAQ:AIMD) a annoncé une réclassification selon le GICS dans le secteur Technology Hardware, Storage & Peripherals (Code 45202030), à effet le 1er octobre 2025. L'entreprise, en transition depuis la biotechnologie, se positionne comme une innovatrice technologique dans l'olfaction numérique avec sa plateforme AI Nose propulsée par le modèle de langage des odeurs (SLM).
Parmi les réalisations clés, une croissance de 435% du chiffre d'affaires annualisée au 1er semestre 2025 tirée par des initiatives de soins aux personnes âgées au Japon et la signature d'un contrat pluriannuel de souscription SmellTech-as-a-Service d'un montant de 2,1 millions de dollars pour la fabrication de semi-conducteurs. Ainos a établi des partenariats stratégiques avec cinq leaders de l'industrie : ASE Technology Holding, Topco Scientific, Kenmec Mechanical Engineering, Solomon Technology et ugo, Inc., afin d'accélérer l'adoption de SmellTech dans les secteurs des semi-conducteurs, de la robotique et de l'automatisation.
Ainos (NASDAQ:AIMD) hat gemäß GICS eine Neubewertung in den Sektor Technology Hardware, Storage & Peripherals (Code 45202030) erhalten, wirksam ab dem 1. Oktober 2025. Das Unternehmen, das sich von der Biotechnologie abwendet, positioniert sich als Technologieinnovator im Bereich der digitalen Riechtechnologie mit seiner AI Nose-Plattform, unterstützt durch das Geruchs-Sprachmodell (SLM).
Zu den wichtigsten Errungenschaften gehört ein 435%-iges Umsatzwachstum im Jahresvergleich im ersten Halbjahr 2025 durch Initiativen im Pflegebereich in Japan sowie der Abschluss eines 2,1 Mio. USD umfassenden Mehrjahresvertrags für SmellTech-as-a-Service für die Halbleiterherstellung. Ainos hat strategische Partnerschaften mit fünf Branchenführern geschlossen: ASE Technology Holding, Topco Scientific, Kenmec Mechanical Engineering, Solomon Technology und ugo, Inc., um die Verbreitung von SmellTech über Halbleiter, Robotik und Automatisierung zu beschleunigen.
Ainos (NASDAQ:AIMD) أُعلنت عن إعادة تصنيفها وفق GICS إلى قطاع أجهزة الكمبيوتر والمواد الطرفية والتخزين (Code 45202030)، ليصبح ساري المفعول اعتباراً من 1 أكتوبر 2025. החברה، التي تتحول من biotechnology، تضع نفسها كمبتكر تكنولوجي في مجال الشم الرقمي من خلال منصتها AI Nose مدعوم بنموذج لغة الشم (SLM).
من أبرز الإنجازات نمو الإيرادات بنسبة 435% على أساس سنوي في النصف الأول من 2025 من مبادرات رعاية كبار السن في اليابان وتأمين عقد اشتراك SmellTech-as-a-Service متعدد السنوات بقيمة $2.1 مليون لصناعة semiconductors. أيمينوس عقدت شراكات استراتيجية مع خمسة قادة صناعيين: ASE Technology Holding, Topco Scientific, Kenmec Mechanical Engineering, Solomon Technology, وugo, Inc., وذلك لتسريع تبني SmellTech عبر قطاعات أشباه الموصلات والروبوتات والأتمتة.
Ainos (NASDAQ:AIMD) 已根据 GICS 重新分类至 Technology Hardware, Storage & Peripherals 行业（代码 45202030），自 2025 年 10 月 1 日起生效。该公司正从生物技术转型，定位为数字嗅觉技术的技术创新者，推出其 AI Nose 平台，由嗅觉语言模型 (SLM) 驱动。
主要成就包括在 2025 年上半年实现对 senior care 项目的 同比增长 435% 的收入增长，以及为半导体制造获得价值 210 万美元的多年度 SmellTech-as-a-Service 订阅合同。Ainos 已与五家行业领军企业建立战略伙伴关系：ASE Technology Holding、Topco Scientific、Kenmec Mechanical Engineering、Solomon Technology、及 ugo, Inc.，以促进 SmellTech 在半导体、机器人技术和自动化领域的采用。
- 435% year-over-year revenue growth in 1H 2025
- Secured first multi-year SaaS contract worth $2.1 million
- Strategic partnerships with five industry leaders in semiconductors and robotics
- Expansion into high-value industries through seven pilot sites in Japan
- None.
Insights
Ainos' GICS reclassification reflects its transformation from biotech to AI technology, supported by 435% revenue growth and new industrial partnerships.
Ainos' reclassification from biotechnology to Technology Hardware, Storage & Peripherals (GICS code 45202030) represents a significant strategic pivot. This change reflects the company's evolution into digital olfaction technology powered by its AI Nose platform and smell language model (SLM).
The financial indicators validate this transformation. Ainos reported a
The five strategic partnerships with ASE Technology Holding, Topco Scientific, Kenmec Mechanical Engineering, Solomon Technology, and ugo, Inc. significantly strengthen Ainos' industrial positioning. These collaborations span semiconductors, robotics, and automation sectors, providing Ainos with distribution channels and integration opportunities across high-value manufacturing industries.
The company's technology platform digitizes scent into machine-readable data, creating a unique position at the intersection of sensory AI and industrial applications. By establishing seven pilot sites across Japan with its robotic partner, Ainos is methodically scaling its technology deployment beyond proof-of-concept.
This reclassification will likely change how investors evaluate Ainos, shifting focus from biotech metrics to technology valuation frameworks that prioritize recurring revenue, user adoption, and platform scalability. As Ainos continues transitioning from project-based revenue to a subscription model, its financial profile will increasingly resemble a technology service provider rather than a research-driven biotech firm.
Five strategic industrial partnerships accelerate AI Nose adoption across semiconductors, robotics, smart manufacturing, and healthcare
SAN DIEGO, CALIFORNIA / ACCESS Newswire / October 2, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a leader in AI-powered scent digitization, today announced its reclassification under the Global Industry Classification Standard (GICS®) to Technology Hardware, Storage & Peripherals (Code 45202030), effective October 1, 2025. The update, administered by S&P Dow Jones Indices and MSCI, marks Ainos' transition from biotechnology to the emerging field of digital olfaction-positioning the Company as a technology innovator enabling artificial intelligence to sense smell.
Ainos' proprietary AI Nose platform, powered by smell language model (SLM), digitizes scent into machine-readable insights, powering new commercial applications across semiconductors, robotics, smart manufacturing, and healthcare. The Company's senior care initiatives in Japan contributed to a
The Company has also strengthened its industrial and geographic footprint through partnerships with five leaders in semiconductors, robotics and automation: ASE Technology Holding, Topco Scientific, Kenmec Mechanical Engineering, Solomon Technology and ugo, Inc. Together, these collaborations accelerate adoption of SmellTech across high-value industries, reinforcing Ainos' competitive position in the global technology value chain for AI infrastructure.
"Our reclassification under GICS is a recognition of Ainos' transformation into a technology company and our growing leadership in AI-powered scent digitization," said Eddy Tsai, Chairman, President, and Chief Executive Officer of Ainos. "This milestone affirms the commercial progress we have achieved and aligns with our long-term vision to establish AI Nose as a foundational AI SmellTech platform. As we scale deployments and expand recurring revenues, we are committed to delivering sustained value to our shareholders and partners worldwide."
About AI Nose
AI Nose digitizes scent into Smell ID, an AI-driven scent intelligence. This full-stack electronic nose (e-nose) platform combines precision MEMS sensor arrays with proprietary AI algorithms, aiming to detect scent at parts-per-billion (ppb) sensitivity. Smell ID then converts analog scent data into actionable insights, while the proprietary smell language model (SLM) learns complex scent patterns. Backed by a 13-year scent data moat and deep medtech expertise, AI Nose aims to deliver continuous monitoring, predictive analytics, and instant alerts to boost safety, quality, and efficiency. To be delivered as SmellTech-as-a-Service, it aims to offer subscription access to ongoing scent intelligence, analytics, and real-time alerts, turning the invisible into strategic advantage.
About Ainos, Inc.
Ainos, Inc. (NASDAQ:AIMD) is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA®, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. Ainos, a fusion of "AI" and "Nose," is redefining machine perception for the sensory age. To learn more, visit https://www.ainos.com. Follow Ainos on X, formerly known as Twitter, (@AinosInc) and LinkedIn to stay up-to-date.
Forward-Looking Statements
Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.
Contact Information
Feifei Shen
ir@ainos.com
SOURCE: Ainos, Inc.
View the original press release on ACCESS Newswire
FAQ
What is Ainos' new GICS classification and when is it effective?
How much revenue growth did Ainos (AIMD) report in first half 2025?
What is the value of Ainos' first SmellTech-as-a-Service contract?
Who are Ainos' strategic partners for AI Nose technology?
What industries is Ainos targeting with its AI Nose platform?
